UY32816A - Formulación farmacéutica a base de 1-[2-(2,1,3-benzotiadiazol-5-ilamino)-6(2,6-diclorofenil)-pirido[2,3-d] pirimidin-7-il]-3-tert-butil-uréa - Google Patents

Formulación farmacéutica a base de 1-[2-(2,1,3-benzotiadiazol-5-ilamino)-6(2,6-diclorofenil)-pirido[2,3-d] pirimidin-7-il]-3-tert-butil-uréa

Info

Publication number
UY32816A
UY32816A UY0001032816A UY32816A UY32816A UY 32816 A UY32816 A UY 32816A UY 0001032816 A UY0001032816 A UY 0001032816A UY 32816 A UY32816 A UY 32816A UY 32816 A UY32816 A UY 32816A
Authority
UY
Uruguay
Prior art keywords
uréa
benzotiadiazol
diclorofenil
pirido
pirimidin
Prior art date
Application number
UY0001032816A
Other languages
English (en)
Inventor
Burnouf Jean Pierre
Tsiala Benard
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of UY32816A publication Critical patent/UY32816A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)

Abstract

La invención se refiere a una formulación que comprende como principio activo el compuesto de fórmula (I): o una sal de este compuesto con un ácido farmacéuticamente aceptable.
UY0001032816A 2009-07-30 2010-07-30 Formulación farmacéutica a base de 1-[2-(2,1,3-benzotiadiazol-5-ilamino)-6(2,6-diclorofenil)-pirido[2,3-d] pirimidin-7-il]-3-tert-butil-uréa UY32816A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0903742A FR2948568B1 (fr) 2009-07-30 2009-07-30 Formulation pharmaceutique

Publications (1)

Publication Number Publication Date
UY32816A true UY32816A (es) 2011-02-28

Family

ID=41570922

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001032816A UY32816A (es) 2009-07-30 2010-07-30 Formulación farmacéutica a base de 1-[2-(2,1,3-benzotiadiazol-5-ilamino)-6(2,6-diclorofenil)-pirido[2,3-d] pirimidin-7-il]-3-tert-butil-uréa

Country Status (40)

Country Link
US (1) US20120202831A1 (es)
EP (1) EP2459221B1 (es)
JP (1) JP5658754B2 (es)
KR (1) KR20120052943A (es)
CN (1) CN102470176B (es)
AR (1) AR077338A1 (es)
AU (1) AU2010277406B2 (es)
BR (1) BR112012002105A2 (es)
CA (1) CA2769477A1 (es)
CL (1) CL2012000231A1 (es)
CO (1) CO6491065A2 (es)
CR (1) CR20120047A (es)
CY (1) CY1115043T1 (es)
DK (1) DK2459221T3 (es)
DO (1) DOP2012000011A (es)
EA (1) EA021059B1 (es)
ES (1) ES2458419T3 (es)
FR (1) FR2948568B1 (es)
HK (1) HK1169960A1 (es)
HN (1) HN2012000182A (es)
HR (1) HRP20140355T1 (es)
IL (1) IL217762A0 (es)
MA (1) MA33462B1 (es)
MX (1) MX2012001386A (es)
MY (1) MY183312A (es)
NI (1) NI201200017A (es)
NZ (1) NZ597963A (es)
PE (1) PE20120619A1 (es)
PL (1) PL2459221T3 (es)
PT (1) PT2459221E (es)
RS (1) RS53266B (es)
SG (1) SG177754A1 (es)
SI (1) SI2459221T1 (es)
SM (1) SMT201400069B (es)
TN (1) TN2011000659A1 (es)
TW (1) TWI478921B (es)
UA (1) UA105229C2 (es)
UY (1) UY32816A (es)
WO (1) WO2011012816A2 (es)
ZA (1) ZA201200719B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
PT3495367T (pt) 2012-06-13 2020-11-12 Incyte Holdings Corp Compostos tricíclicos substituídos como inibidores de fgfr
WO2014026125A1 (en) 2012-08-10 2014-02-13 Incyte Corporation Pyrazine derivatives as fgfr inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
TWI715901B (zh) 2013-04-19 2021-01-11 美商英塞特控股公司 作為ｆｇｆｒ抑制劑之雙環雜環
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
CN113004278B (zh) 2015-02-20 2023-07-21 因赛特控股公司 作为fgfr抑制剂的双环杂环
WO2016134294A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
WO2019213544A2 (en) 2018-05-04 2019-11-07 Incyte Corporation Solid forms of an fgfr inhibitor and processes for preparing the same
CR20200591A (es) 2018-05-04 2021-03-31 Incyte Corp Sales de un inhibidor de fgfr
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
TW202128685A (zh) 2019-10-14 2021-08-01 美商英塞特公司 作為ｆｇｆｒ抑制劑之雙環雜環
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
EP4069696A1 (en) 2019-12-04 2022-10-12 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
CA3162010A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Derivatives of an fgfr inhibitor
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
CA3220274A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2911241A1 (de) 1979-03-22 1980-10-02 Basf Ag Alkoxylierte fettsaeuren, verfahren zu deren herstellung und ihre anwendung als loesungsvermittler
HU201567B (en) * 1988-07-21 1990-11-28 Gyogyszerkutato Intezet Process for production of intravenous medical compositions containing cyclosphorin
PL319511A1 (en) * 1994-10-05 1997-08-18 Glaxo Wellcome Inc Parenteral pharmaceutic compositions containing gf120918a
US5922754A (en) * 1998-10-02 1999-07-13 Abbott Laboratories Pharmaceutical compositions containing paclitaxel
US8618085B2 (en) * 2000-04-28 2013-12-31 Koasn Biosciences Incorporated Therapeutic formulations of desoxyepothilones
KR100866728B1 (ko) * 2004-11-12 2008-11-03 주식회사종근당 타크로리무스를 함유하는 주사제
FR2879932B1 (fr) * 2004-12-27 2007-03-23 Aventis Pharma Sa Formulations injectable ou administrable par voie orale de derives d'azetidine
FR2887882B1 (fr) 2005-07-01 2007-09-07 Sanofi Aventis Sa Derives de pyrido[2,3-d] pyrimidine, leur preparation, leur application en therapeutique
FR2910813B1 (fr) * 2006-12-28 2009-02-06 Sanofi Aventis Sa Nouvelle utilisation therapeutique pour le traitement des leucemies
DE102007021862A1 (de) * 2007-05-10 2008-11-13 Merck Patent Gmbh Wässrige pharmazeutische Zubereitung

Also Published As

Publication number Publication date
PE20120619A1 (es) 2012-05-29
TWI478921B (zh) 2015-04-01
MX2012001386A (es) 2012-06-01
NI201200017A (es) 2012-05-24
TN2011000659A1 (fr) 2013-05-24
ZA201200719B (en) 2013-05-29
AU2010277406A1 (en) 2012-02-23
AR077338A1 (es) 2011-08-17
CN102470176B (zh) 2015-07-29
TW201120036A (en) 2011-06-16
BR112012002105A2 (pt) 2019-09-24
SG177754A1 (en) 2012-03-29
CL2012000231A1 (es) 2012-09-14
EA021059B1 (ru) 2015-03-31
KR20120052943A (ko) 2012-05-24
SMT201400069B (it) 2014-07-07
PL2459221T3 (pl) 2014-06-30
CA2769477A1 (fr) 2011-02-03
DK2459221T3 (da) 2014-04-22
SI2459221T1 (sl) 2014-05-30
EP2459221B1 (fr) 2014-01-22
IL217762A0 (en) 2012-03-29
MA33462B1 (fr) 2012-07-03
FR2948568B1 (fr) 2012-08-24
WO2011012816A2 (fr) 2011-02-03
HN2012000182A (es) 2014-11-10
FR2948568A1 (fr) 2011-02-04
EA201270216A1 (ru) 2012-06-29
WO2011012816A3 (fr) 2011-12-22
AU2010277406B2 (en) 2015-11-12
HK1169960A1 (en) 2013-02-15
US20120202831A1 (en) 2012-08-09
CY1115043T1 (el) 2016-12-14
JP5658754B2 (ja) 2015-01-28
EP2459221A2 (fr) 2012-06-06
RS53266B (en) 2014-08-29
NZ597963A (en) 2014-02-28
HRP20140355T1 (hr) 2014-06-20
CO6491065A2 (es) 2012-07-31
CR20120047A (es) 2012-06-01
JP2013500321A (ja) 2013-01-07
ES2458419T3 (es) 2014-05-05
CN102470176A (zh) 2012-05-23
UA105229C2 (uk) 2014-04-25
PT2459221E (pt) 2014-04-30
DOP2012000011A (es) 2012-02-29
MY183312A (en) 2021-02-18

Similar Documents

Publication Publication Date Title
UY32816A (es) Formulación farmacéutica a base de 1-[2-(2,1,3-benzotiadiazol-5-ilamino)-6(2,6-diclorofenil)-pirido[2,3-d] pirimidin-7-il]-3-tert-butil-uréa
CY1118093T1 (el) Φαρμακοτεχνικες μορφες που περιλαμβανουν παραγωγα 1-(bhta-d-γλυκοπυρανοζυλ)-2-θειενυλμεθυλβενζολιου ως αναστολεις sglt
WO2014002051A3 (en) Complement pathway modulators and uses thereof
IN2015DN00185A (es)
EA201201263A1 (ru) Фармацевтическая композиция, содержащая этексилат дабигатрана
WO2014002058A3 (en) Complement pathway modulators and uses thereof
IT1404931B1 (it) Composizioni oftalmiche per la somministrazione di principi attivi liposolubili .
PH12015501752A1 (en) Substituted bisphenyl butanoic phosphonic acid derivatives as nep inhibitors
EA201201050A1 (ru) Пиразолы в качестве антагонистов crth2
EA201201202A1 (ru) Пероральная фармацевтическая композиция, содержащая этексилат дабигатрана
MY168212A (en) A new therapeutical composition containing apomorphine as active ingredient
WO2010130773A3 (en) Benzoxazolone derivatives as aldosterone symthase inhibitors
WO2012140596A8 (en) Glycoside derivatives and uses thereof
IN2012DN04868A (es)
TN2014000060A1 (en) Benzothiazolone compound
ES2531312T3 (es) Formulaciones, sales y polimorfos de transnorsertralina y usos de los mismos
MX2016006667A (es) Derivados de pirrolo-pirrolona y su uso como inhibidores.
MX2015010434A (es) Derivados de acido bisfenil-butanoico sustituido como inhibidores de la endopeptidasa neutra (nep), con una mayor eficacia in vivo.
MX2012007393A (es) Composicion farmaceutica de disolucion rapida comprendiendo lornoxicam.
WO2013062332A3 (ko) 시링가레시놀을 포함하는 혈관 노화 억제용 조성물
TR200802061A2 (tr) Yüksek oranda aktif madde içeren farmasötlk formülasyon.
TN2015000058A1 (en) Salts of benzothiazolone compound as beta-2-adrenoceptor agonist
TN2012000617A1 (en) 2,3,5-trisubstituted thiophene compounds and uses thereof
IN2013MU02442A (es)

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20190214